Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | HTR1D | P28221 | 4/20 | 0.53 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.53 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8645214 | 0.94 | MAPT (0.64) | HTR1BKMT2AMAPTMEN1GFER | |
| Oxalic Acid SCHEMBL7540449 | 0.81 | HTR1B (0.66) | HTR1BKMT2AMEN1SMN1; SMN2HTR6 | |
| Oxalic Acid SCHEMBL7543349 | 0.81 | HTR1B (0.66) | HTR1BKMT2AHTR6HTR1DBAZ2B | |
| Oxalic Acid SCHEMBL8648568 | 0.80 | HTR1B (0.44) | HTR1BKMT2AMAPTMEN1GFER | |
| SCHEMBL6757984 | 0.80 | KMT2A (0.64) | HTR1BKMT2AMAPTMEN1GFER | |
| Oxalic Acid SCHEMBL9286576 | 0.79 | HTR1B (0.49) | HTR1BKMT2AMAPTMEN1GFER | |
| Oxalic Acid SCHEMBL7540885 | 0.78 | HTR1B (0.62) | HTR1BKMT2AMEN1HTR6HTR1D | |
| SCHEMBL11205154 | 0.78 | MAPT (0.58) | KMT2AMAPTMEN1GFERSMN1; SMN2 | |
| Oxalic Acid SCHEMBL8642606 | 0.78 | HTR6 (0.44) | HTR1BKMT2AMAPTMEN1SMN1; SMN2 | |
| Oxalic Acid SCHEMBL27314563 | 0.77 | HTR1B (0.71) | HTR1BKMT2AMAPTMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032192-A1 | Treatment of vasodilatory headache | VERNALIS LIMITED (GB) | 2002-03-14 | — | — | US | disclosed |
| EP-1175416-A1 | HETEROARYL DIAZACYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-30 | — | — | EP | disclosed |
| EP-1104292-A2 | TREATMENT OF VASODILATORY HEADACHE | Vernalis Limited (GB) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000064885-A1 | HETEROARYL DIAZACYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-11-02 | — | — | WO | disclosed |
| WO-2000009099-A2 | TREATMENT OF VASODILATORY HEADACHE | VERNALIS LIMITED (GB) | 2000-02-24 | — | — | WO | disclosed |
| US-5827871-A | VASODILATION DISORDERS, ESPECIALLY MIGRAINE HEADACHES; SIDE EFFECT REDUCTION | SMITHKLINE BEECHAM PLC (GB) | 1998-10-27 | — | — | US | disclosed |
| EP-0603432-B1 | Tetrahydrocarbazole derivatives for the manufacture of a medicament for the treatment of a disease where a 5-HT1-like agonist is indicated | SMITHKLINE BEECHAM PLC (GB) | 1998-10-21 | — | — | EP | disclosed |
| EP-0591280-B1 | USE OF TETRAHYDROCARBAZOLE DERIVATIVES AS 5HT1-RECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-09 | — | — | EP | disclosed |
| US-5637611-A | Medicaments | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-06-10 | — | — | US | disclosed |
| CN-1034072-C | Medicaments | SMITHKLINE BEECHAM PLC (GB) | 1997-02-19 | — | — | CN | disclosed |
| US-5464864-A | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-11-07 | — | — | US | disclosed |
| EP-0603432-A1 | Tetrahydrocarbazole derivatives for the manufacture of a medicament for the treatment of a disease where a 5-HT1-like agonist is indicated | SMITHKLINE BEECHAM PLC (GB) | 1994-06-29 | — | — | EP | disclosed |
| EP-0591280-A1 | USE OF TETRAHYDROCARBAZOLE DERIVATIVES AS 5HT1-RECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-04-13 | — | — | EP | disclosed |
| CN-1069726-A | The preparation method of compounds | SMITHKLINE BEECHAM PLC (GB) | 1993-03-10 | — | — | CN | disclosed |
| WO-1993000086-A1 | USE OF TETRAHYDROCARBAZONE DERIVATIVES AS 5HT1 RECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032192-A1 | Treatment of vasodilatory headache | CNR1, CNR2, EDNRA | HTR1B 71/4885KMT2A 2511/4885MAPT 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.